the element that stands out the most to me is that Sonic look to be in line for $330 revenue per test, assuming 15% royalty to PIQ. With 2 million diabetes patients already on their books, let's say they convert 20% of those and the tests are used for ongoing evaluation that's a walk up $198m AUD (using 1.5 USD:AUD) revenue per annum and providing $36m AUD royalty to PIQ. As Sonic, it would seem acquiring PIQ even at a multiple of current MC ($98m) to capture the $36m AUD per annum would seem a no brainer. on the flip, maybe they see the potential but prefer to wait for the platform to be developed and other tests approved etc
who knows. it just seems cheap.
the element that stands out the most to me is that Sonic look to...
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.015(1.41%) |
Mkt cap ! $137.4M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.06 | $1.02 | $136.4K | 131.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 443 | 1 |
View Market Depth
| Last trade - 15.52pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.05 |
Change
-0.015 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.05 | $1.06 | $1.03 | 34377 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| PIQ (ASX) Chart |